A Review of Therapeutic Aptamer Conjugates with Emphasis on New Approaches

Hansel, 2010, The safety and side effects of monoclonal antibodies, Nat. Rev. Drug Discov., 9, 325, 10.1038/nrd3003

Hedden, 2012, Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer, Oncologist, 17, 164, 10.1634/theoncologist.2011-0379

Jeyakumar, 2012, Trastuzumab for HER2-positive metastatic breast cancer: clinical and economic considerations, Clin. Med. Insights Oncol., 6, 179, 10.4137/CMO.S6460

Goncalves, 2009, Cost-effectiveness analysis of trastuzumab (Herceptin) in HER2-overexpressed metastatic breast cancer, Am. J. Clin. Oncol., 32, 492, 10.1097/COC.0b013e3181931277

Harding, 2010, The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions, MAbs, 2, 256, 10.4161/mabs.2.3.11641

Meng, 2012, Targeted delivery of chemotherapy agents using a liver cancer-specific aptamer, PLoS One, 7, e33434, 10.1371/journal.pone.0033434

Bolhassani, 2011, Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer, Biochim. Biophys. Acta, 1816, 232

Koren, 2012, Cell-penetrating peptides: breaking through to the other side, Trends Mol. Med., 18, 385, 10.1016/j.molmed.2012.04.012

Lehto, 2012, Cell-penetrating peptides for the delivery of nucleic acids, Expert Opin. Drug Deliv., 9, 823, 10.1517/17425247.2012.689285

Bruno, 2009, Preliminary development of DNA aptamer-Fc conjugate opsonins, J. Biomed. Mat. Res. A, 90, 1152, 10.1002/jbm.a.32182

Bruno, 2008, In vitro antibacterial effects of anti-lipopolysaccharide DNA aptamer-C1qrs complexes, Folia Microbiol., 53, 295, 10.1007/s12223-008-0046-6

Bruno, 2010, Aptamer-biotin-streptavidin-C1q complexes can trigger the classical complement pathway to kill cancer cells, In Vitro Cell. Dev. Biol., 46, 107, 10.1007/s11626-009-9257-7

Bruno, J.G., and Miner, J.C. (2013). Therapeutic nucleic acid-3'—Conjugates. (Nos. 7,910,297, 8,318,920, and 8,389,710), U.S. Patent.

Hakulinen, 1998, Complement-mediated killing of microtumors in vitro, Am. J. Path., 153, 845, 10.1016/S0002-9440(10)65626-X

Stecker, 2012, Dynamics and visualization of MCF7 adenocarcinoma cell death by aptamer-C1q-mediated membrane attack, Nucleic Acid Ther., 22, 275, 10.1089/nat.2012.0355

Chu, 2006, Aptamer:toxin conjugates that specifically target prostate tumor cells, Cancer Res., 66, 5989, 10.1158/0008-5472.CAN-05-4583

Bagalkot, 2006, An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform, Angew. Chem. Int. Ed. Eng., 45, 8149, 10.1002/anie.200602251

Huang, 2009, Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells, Chembiochem., 10, 862, 10.1002/cbic.200800805

Tan, 2011, Molecular aptamers for drug delivery, Trends Biotechnol., 29, 634, 10.1016/j.tibtech.2011.06.009

Borbas, 2007, Design and synthesis of mono- and multimeric targeted radiopharmaceuticals based on novel cyclen ligands coupled to anti-MUC1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer, Bioconj. Chem., 18, 1205, 10.1021/bc0700741

Perkins, 2009, Anti-MUC1 aptamers: radiolabelling with (99m) Tc and biodistribution in MCF-7 tumour-bearing mice, Nucl. Med. Biol., 36, 703, 10.1016/j.nucmedbio.2009.04.004

Bakalova, 2004, Quantum dots as photosensitizers?, Nat. Biotechnol., 22, 1360, 10.1038/nbt1104-1360

Dwarakanath, 2007, Antibody-quantum dot conjugates exhibit enhanced antibacterial effect vs. unconjugated quantum dots, Folia Microbiol., 52, 31, 10.1007/BF02932134

Ferreira, 2009, Phototoxic aptamers selectively enter and kill epithelial cancer cells, Nucleic Acids Res., 37, 866, 10.1093/nar/gkn967

Jin, 2009, Antimicrobial efficacy of zinc oxide quantum dots against Listeria monocytogenes, Salmonella enteritidis, and Escherichia coli O157:H7, J. Food Sci., 74, 46, 10.1111/j.1750-3841.2008.01013.x

Samia, 2006, Quantum dot-based energy transfer: perspectives and potential for applications in photodynamic therapy, Photochem. Photobiol., 82, 617, 10.1562/2005-05-11-IR-525

Shi, 2006, Singlet oxygen generation from water-soluble quantum dot-organic dye nanocomposites, J. Am. Chem. Soc., 128, 6278, 10.1021/ja057959c

Yang, 2011, Angiogenin-mediated photosensitizer-aptamer conjugate for photodynamic therapy, Chem. Med. Chem., 6, 1778, 10.1002/cmdc.201100226

Yang, 2012, Near-infrared light-triggered, targeted drug delivery to cancer cells by aptamer-gated nanovehicles, Adv. Mater., 24, 2890, 10.1002/adma.201104797

Beqa, 2011, Gold nano-popcorn attached SWCNT hybrid nanomaterial for targeted diagnosis and photothermal therapy of human breast cancer cells, ACS Appl. Mater. Interfaces, 3, 3316, 10.1021/am2004366

Farokhzad, 2006, Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo, Proc. Natl. Acad. Sci. USA, 103, 6315, 10.1073/pnas.0601755103

Huang, 2008, Cancer cell targeting using multiple aptamers conjugated on nanorods, Anal. Chem., 80, 567, 10.1021/ac702322j

Huang, 2008, Selective photothermal therapy for mixed cancer cells using aptamer-conjugated nanorods, Langmuir, 24, 11860, 10.1021/la801969c

Li, 2012, Polyvalent mesoporous silica nanoparticle-aptamer bioconjugates target breast cancer cells, Adv. Health Mater., 1, 567, 10.1002/adhm.201200116

Liu, 2009, Sharper and faster “nano darts” kill more bacteria: A study of antibacterial activity of individually dispersed pristine single-walled carbon nanotube, ACS Nano, 3, 3891, 10.1021/nn901252r

Wang, 2012, Assembly of aptamer switch probes and photosensitizer on gold nanorods for targeted photothermal and photodynamic cancer therapy, ACS Nano, 6, 5070, 10.1021/nn300694v

Yang, 2011, Aptamer-conjugated nanomaterials and their applications, Adv. Drug Deliv. Rev., 63, 1361, 10.1016/j.addr.2011.10.002

Berezhnoy, 2012, Thermal stability of siRNA modulates aptamer-conjugated siRNA inhibition, Mol. Ther. Nucl. Acids, 1, e51, 10.1038/mtna.2012.41

Dassie, 2009, Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors, Nat. Biotechnol., 27, 839, 10.1038/nbt.1560

Neff, 2011, An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4 (+) T cell decline in humanized mice, Sci. Transl. Med., 3, 66ra6, 10.1126/scitranslmed.3001581

Zhou, 2012, Current progress of RNA aptamer-based therapeutics, Front. Genet., 3, 1, 10.3389/fgene.2012.00234

Zhou, 2010, Aptamer-targeted cell-specific RNA interference, Silence, 1, 4, 10.1186/1758-907X-1-4

Bruno, 2008, Selective glutaraldehyde-mediated coupling of proteins to the 3' adenine terminus of Polymerase Chain Reaction products, J. Biomolec. Techn., 19, 177

Bruno, J.G. (2013). Biomedical Applications of Aptamers, Nova Science Publishers.

Aarons, 1983, The binding of ibuprofen to plasma proteins, Eur. J. Clin. Pharmacol., 25, 815, 10.1007/BF00542526

Cheruvallath, 1997, A quantitative circular dichroic investigation of the binding of the enantiomers of ibuprofen and naproxen to human serum albumin, J. Pharm. Biomed. Anal., 15, 1719, 10.1016/S0731-7085(96)01956-5

Manoharan, M., Rajeev, K.G., and Kesavan, V. (2009). Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety. (No. 12/604,897, filed), U.S. Patent Application.

Stasiak, 2010, In vivo assessment of parenteral formulations of oligo (3-hydroxybutyric acid) conjugates with the model compound ibuprofen, AAPS Pharm. Sci. Tech., 11, 1636, 10.1208/s12249-010-9545-2

Zion, T.C., and Lancaster, T.M. (2011). Polynucleotide aptamers-based cross-linked materials and uses thereof. (No. 13/145,531), U.S. Patent Application.

Zsila, 2011, Evaluation of drug-human serum albumin binding interactions with support vector machine aided online automated docking, Bioinformatics, 27, 1806, 10.1093/bioinformatics/btr284

Wright, 2012, Immunotherapy of breast cancer, Expert Opin. Biol. Ther., 12, 479, 10.1517/14712598.2012.665445

Wu, 2005, Arming antibodies: prospects and challenges for immunoconjugates, Nat. Biotechnol., 23, 1137, 10.1038/nbt1141

Bruno, 2012, Development, screening, and analysis of a small DNA aptamer library potentially useful for diagnosis and passive immunity of arboviruses, BMC Res. Notes, 5, 633, 10.1186/1756-0500-5-633

Chen, 2013, Function of ssDNA aptamer and aptamer pool against Mycobacterium tuberculosis in a mouse model, Mol. Med. Rep., 7, 669, 10.3892/mmr.2012.1229

Cheng, 2008, Potent inhibition of human influenza H5N1 virus by oligonucleotides derived by SELEX, Biochem. Biophys. Res. Commun., 366, 670, 10.1016/j.bbrc.2007.11.183

Mullis, K.B. Chemically programmable immunity. (Nos. 7,422,746, 7,645,743, 7,850,795, 8,236,321, and 8,263,082), U.S. Patent.

Bruno, J.G. (2013). Biomedical Applications of Aptamers, Nova Science Publishers.

Fan, 2008, Protective effects of anti-ricin A-chain RNA aptamer against ricin toxicity, World J. Gastroenterol., 14, 6360, 10.3748/wjg.14.6360

Lauridsen, 2012, Nucleic acid aptamers against biotoxins: A new paradigm toward the treatment and diagnostic approach, Nucleic Acid Ther., 22, 371, 10.1089/nat.2012.0377

Dobler, R.K., and Maki, W.C. (2005, January 4–5). Mars health care delivery systems: Aptamers provide critical technology. 12th NASA Symposium of VLSA Design, Coeur d'Alene, ID, USA.

Healy, 2004, Pharmacokinetics and biodistribution of novel aptamer compositions, Pharm. Res., 21, 2234, 10.1007/s11095-004-7676-4

King, 1998, Novel combinatorial selection of phosphorothioate oligonucleotide aptamers, Biochemistry, 37, 16489, 10.1021/bi981780f

Klussmann, S. (2006). The Aptamer. Handbook, Wiley-VCH, Verlag GmBH & Co.

Eulberg, 2003, Spiegelmers: Biostable aptamers, Chembiochem, 4, 979, 10.1002/cbic.200300663

Klussmann, S. (2006). The Aptamer. Handbook, Wiley-VCH, Verlag GmBH & Co.

Boomer, 2005, Conjugation to polyethylene glycol polymer promotes aptamer biodistribution to healthy and inflamed tissues, Oligonucleotides, 15, 183, 10.1089/oli.2005.15.183

Blackshaw, 2012, PEGylation and biodistribution of an anti-MUC1 aptamer in MCF-7 tumor-bearing mice, Bioconjug. Chem., 237, 1377

Nordhoff, 1994, Synthesis and properties of oligodeoxyribonucleotide-polyethylene glycol conjugates, Nucleic Acids Res., 22, 4810, 10.1093/nar/22.22.4810

Dougan, 2000, Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood, Nucl. Med. Biol., 27, 289, 10.1016/S0969-8051(99)00103-1

Farkas, 2002, CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9, J. Physiol., 539, 537, 10.1113/jphysiol.2001.013381

Dominguez, 2003, Early mechanisms of Leishmania. infection in human blood, Microbes Infect., 5, 507, 10.1016/S1286-4579(03)00071-6

Carter, 2011, Coupling strategies for the synthesis of peptide-oligonucleotide conjugates for patterned synthetic biomineralization, J. Nucleic Acids., 2011, 926595, 10.4061/2011/926595

Hasegawa, 2008, Improvement of aptamer affinity by dimerization, Sensors, 8, 1090, 10.3390/s8021090

Mallikaratchy, 2011, A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia, Nucleic Acids Res., 39, 2458, 10.1093/nar/gkq996

Tian, 2009, Bivalent ligands with long nanometer-scale flexible linkers, Biochemistry, 48, 264, 10.1021/bi801630b

Yang, 2011, Engineering polymeric aptamers for selective cytotoxicity, J. Am. Chem. Soc., 133, 13380, 10.1021/ja201285y

Murray, E., Gregg, D.A., Norton, M.L., Swick, J.T., and Towler, W.I. (2012). Method for a continuous rapid thermal cycle system. (No. 8,163,489), U.S. Patent.

Wahajuddin, 2012, Superparamagnetic iron oxide nanoparticles: Magnetic nanoplatforms as drug carriers, Int. J. Nanomed., 7, 3445, 10.2147/IJN.S30320

Nair, 2010, Aptamer conjugated magnetic nanoparticles as nanosurgeons, Nanotechnology, 21, 455102, 10.1088/0957-4484/21/45/455102

Silva, 2011, Application of hyperthermia induced by superparamagnetic iron oxide nanoparticles in glioma treatment, Int. J. Nanomed., 6, 591

Hilger, 2012, Iron oxide-based nanostructures for MRI and magnetic hyperthermia, Nanomedicine, 7, 1443, 10.2217/nnm.12.112

Kobayashi, 2011, Cancer hyperthermia using magnetic nanoparticles, Biotechnol. J., 6, 1342, 10.1002/biot.201100045

Cavaliere, 1967, Selective heat sensitivity of cancer cells. Biochemical and clinical studies, Cancer, 20, 1351, 10.1002/1097-0142(196709)20:9<1351::AID-CNCR2820200902>3.0.CO;2-#

Christophi, 1998, The treatment of malignancy by hyperthermia, Surg. Oncol., 7, 83, 10.1016/S0960-7404(99)00007-9

Sellins, 1991, Hyperthermia induces apoptosis in thymocytes, Radiat. Res., 126, 88, 10.2307/3578175

Glazer, 2011, Non-invasive radiofrequency ablation of malignancies mediated by quantum dots, gold nanoparticles and carbon nanotubes, Ther. Deliv., 2, 1325, 10.4155/tde.11.102

Glazer, 2010, Radiofrequency field-induced thermal cytotoxicity in cancer cells treated with fluorescent nanoparticles, Cancer, 116, 3285, 10.1002/cncr.25135

Glazer, 2010, Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles, Clin. Cancer Res., 16, 5712, 10.1158/1078-0432.CCR-10-2055

Wang, 2011, Study of the bioeffects of CdTe quantum dots on Escherichia coli cells, J. Coll. Interface Sci., 363, 476, 10.1016/j.jcis.2011.08.016

Liu, 2011, CdSe quantum dot (QD)-induced morphological and functional impairments to liver in mice, PLoS One, 6, e24406, 10.1371/journal.pone.0024406

Li, 2009, Intracellular oxidative stress and cadmium ions release induce cytotoxicity of unmodified cadmium sulfide quantum dots, Toxicol. In Vitro., 23, 1007, 10.1016/j.tiv.2009.06.020

Tsay, 2007, Singlet oxygen production by peptide-coated quantum dot-photosensitizer conjugates, J. Am. Chem. Soc., 129, 6865, 10.1021/ja070713i

Yaghini, 2009, Quantum dots and their potential biomedical applications in photosensitization for photodynamic therapy, Nanomedicine, 4, 353, 10.2217/nnm.09.9

Savla, 2011, Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer, J. Control. Release, 153, 16, 10.1016/j.jconrel.2011.02.015

Taghdisi, 2011, Reversible targeting and controlled release delivery of daunorubicin to cancer cells by aptamer-wrapped carbon nanotubes, Eur. J. Pharm. Biopharm., 77, 200, 10.1016/j.ejpb.2010.12.005

Tan, 2011, Molecular aptamers for drug delivery, Trends Biotechnol., 9, 634, 10.1016/j.tibtech.2011.06.009

Lu, 2010, Gold nano-popcorn-based targeted diagnosis, nanotherapy treatment, and in situ monitoring of photothermal therapy response of prostate cancer cells using surface-enhanced Raman spectroscopy, J. Am. Chem. Soc., 132, 18103, 10.1021/ja104924b

Jarmila, 2011, Chitosan derivatives with antimicrobial, antitumour and antioxidant activities-a review, Curr. Pharm. Des., 17, 3596, 10.2174/138161211798194468

Patel, 2010, Chitosan mediated targeted drug delivery system: A review, J. Pharm. Pharmaceut. Sci., 13, 536

Bowman, 2006, Chitosan nanoparticles for oral drug and gene delivery, Int. J. Nanomedicine, 1, 117, 10.2147/nano.2006.1.2.117

Hassan, 1993, Targeting anticancer drugs to the brain. I: Enhanced brain delivery of oxantrazole following administration in magnetic cationic microspheres, J. Drug Target., 1, 7, 10.3109/10611869308998759

Tallury, 2009, Ultra-small water dispersible fluorescent chitosan nanoparticles: Synthesis, characterization and specific targeting, Chem. Commun., 7, 2347, 10.1039/b901729a

Mann, 2011, Thioaptamer conjugated liposomes for tumor vasculature targeting, Oncotarget, 2, 298, 10.18632/oncotarget.261

Kolhe, 2004, Hyperbranched polymer-drug conjugates with high drug payload for enhanced cellular delivery, Pharm. Res., 21, 2185, 10.1007/s11095-004-7670-x

Kolhe, 2006, Preparation, cellular transport, and activity of polyamidoamine-based dendritic nanodevices with a high drug payload, Biomaterials, 27, 660, 10.1016/j.biomaterials.2005.06.007

Kim, 2008, Molecular assembly for high-performance bivalent nucleic acid inhibitor, Proc. Natl. Acad. Sci. USA, 105, 5664, 10.1073/pnas.0711803105

McNamara, 2008, Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice, J. Clin. Invest., 118, 376, 10.1172/JCI33365

Wachowius, 2011, Probing essential nucleobase functional groups in aptamers and deoxyribozymes by nucleotide analogue interference mapping of DNA, J. Am. Chem. Soc., 133, 14888, 10.1021/ja205894w

Hollenstein, 2011, Expanding the catalytic repertoire of DNAzymes by modified nucleosides, ChimiaInt. J. Chem., 65, 770

Sanghvi, 2011, A status update of modified oligonucleotides for chemotherapeutics applications, Curr. Protoc. Nucleic Acid Chem., 46, 4.1.1, 10.1002/0471142700.nc0401s46

Sundaram, 2013, Therapeutic RNA aptamers in clinical trials, Eur. J. Pharm. Sci., 48, 259, 10.1016/j.ejps.2012.10.014